NASDAQ:MEDP Medpace (MEDP) Stock Price, News & Analysis → Start loving Mondays like this (From DTI) (Ad) Free MEDP Stock Alerts $374.32 -8.12 (-2.12%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$373.99▼$386.2450-Day Range$324.21▼$413.3152-Week Range$185.43▼$419.42Volume219,885 shsAverage Volume170,486 shsMarket Capitalization$11.60 billionP/E Ratio42.15Dividend YieldN/APrice Target$382.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Medpace alerts: Email Address Medpace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside2.1% Upside$382.00 Price TargetShort InterestHealthy3.82% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.90Based on 8 Articles This WeekInsider TradingSelling Shares$76.65 M Sold Last QuarterProj. Earnings Growth20.89%From $10.53 to $12.73 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.48 out of 5 starsMedical Sector85th out of 918 stocksCommercial Physical Research Industry4th out of 11 stocks 1.4 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMedpace has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.82% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medpace has recently decreased by 1.76%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedpace has received a 72.85% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Medical devices engineering", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Medpace is -0.62. Previous Next 2.7 News and Social Media Coverage News SentimentMedpace has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Medpace this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for MEDP on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $76,651,647.00 in company stock.Percentage Held by Insiders20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 20.89% in the coming year, from $10.53 to $12.73 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 42.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.06.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 42.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 165.61.Price to Earnings Growth RatioMedpace has a PEG Ratio of 2.02. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMedpace has a P/B Ratio of 20.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTISpecial FREE offer on stock hotsheetsThese sheets tell you the exact day you should consider buying a stock… And the exact day you should consider selling it… All based on TEN YEARS of historic data and trends. For example, like January 6th through the 12th with Apple… It’s gone up every single year for the last decade. Or like May 26th through June 11th with LULU… Again - it’s gone up every single year for the last decade. Then there’s July 1st through the 21st with Walmart… What happened to WMT?Click here and I’ll show you About Medpace Stock (NASDAQ:MEDP)Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.Read More MEDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDP Stock News HeadlinesMarch 20, 2024 | insidertrades.comInsider Selling: Medpace Holdings, Inc. (NASDAQ:MEDP) VP Sells 102 Shares of StockMarch 19, 2024 | insidertrades.comMedpace Holdings, Inc. (NASDAQ:MEDP) Director Sells $102,467.50 in StockApril 19, 2024 | Darwin (Ad)Your Next Portfolio Star: Revealing 2024's Top Stock Pick We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)April 17, 2024 | msn.comAn iconic bar returns (and the 3 best things I ate last week)April 17, 2024 | markets.businessinsider.comMedpace Holdings Inc hosts conference call for investorsApril 15, 2024 | americanbankingnews.comFinancial Survey: Medpace (NASDAQ:MEDP) and OneMedNet (NASDAQ:ONMD)April 15, 2024 | americanbankingnews.comMedpace (MEDP) to Release Quarterly Earnings on MondayApril 12, 2024 | americanbankingnews.comMedpace Holdings, Inc. (NASDAQ:MEDP) Given Average Rating of "Moderate Buy" by AnalystsApril 19, 2024 | Darwin (Ad)Your Next Portfolio Star: Revealing 2024's Top Stock Pick We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)April 11, 2024 | benzinga.comIf You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,800 TodayApril 8, 2024 | finance.yahoo.comEstimating The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)April 5, 2024 | finance.yahoo.comMedpace Holdings (MEDP) is Maintaining a Healthy Margin ProfileMarch 28, 2024 | businesswire.comMedpace Holdings, Inc. to Report First Quarter 2024 Financial Results on April 22, 2024March 28, 2024 | businesswire.comMedpace Holdings, Inc. to Report First Quarter 2024 Financial Results on April 22, 2024March 28, 2024 | msn.comAlara is Madisonville's newest American restaurant, latest from popular restaurant groupMarch 27, 2024 | msn.comNew restaurant opens in Cincinnati's Madisonville neighborhoodMarch 25, 2024 | bizjournals.comLooking Glass Hospitality announces menu, hours for new $6.5M upscale restaurant, AlaraMarch 22, 2024 | finance.yahoo.comShould You Invest in Medpace (MEDP)?March 22, 2024 | finance.yahoo.comInvestors in Medpace Holdings (NASDAQ:MEDP) have seen enviable returns of 609% over the past five yearsMarch 19, 2024 | finance.yahoo.comDoes Medpace Holdings (MEDP) Have The Potential to Maintain Strong Growth?March 18, 2024 | insidermonkey.comInsiders Are Selling These 5 Stocks in 2024March 17, 2024 | bizjournals.comConvergence of factors powers the innovative ecosystem’s competitive advantage in OhioMarch 16, 2024 | finance.yahoo.comMEDP Apr 2024 580.000 callMarch 15, 2024 | bizjournals.comFive things to know, and Cincinnati chili in the Windy City? I'm a skepticMarch 14, 2024 | bizjournals.comLooking Glass Hospitality announces opening date, menu for newest restaurant venture, AlaraMarch 12, 2024 | uk.finance.yahoo.comPatient Recruitment and Retention Services Global Market Report 2024March 11, 2024 | seekingalpha.comMedpace: Exceptional Performance, Almost Fully Priced InSee More Headlines Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/12/2024Today4/19/2024Next Earnings (Confirmed)4/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:MEDP CUSIPN/A CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,900Year FoundedN/APrice Target and Rating Average Stock Price Target$382.00 High Stock Price Target$452.00 Low Stock Price Target$273.00 Potential Upside/Downside+2.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$8.88 Trailing P/E Ratio42.15 Forward P/E Ratio35.55 P/E Growth2.02Net Income$282.81 million Net Margins15.00% Pretax Margin17.80% Return on Equity63.98% Return on Assets19.02% Debt Debt-to-Equity RatioN/A Current Ratio0.64 Quick Ratio0.64 Sales & Book Value Annual Sales$1.89 billion Price / Sales6.15 Cash Flow$9.86 per share Price / Cash Flow37.96 Book Value$18.22 per share Price / Book20.54Miscellaneous Outstanding Shares30,980,000Free Float24,693,000Market Cap$11.60 billion OptionableOptionable Beta1.38 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. August James Troendle M.D. (Age 68)Chairman & CEO Comp: $1.68MMr. Jesse J. Geiger BBA (Age 50)CPA, President Comp: $876.92kMr. Kevin M. Brady (Age 49)CFO & Treasurer Comp: $636.58kMs. Susan E. Burwig BSN (Age 61)MA, Executive Vice President of Operations Comp: $1MMr. Stephen P. Ewald J.D. (Age 55)Chief Compliance Officer, General Counsel & Corporate Secretary Comp: $826.17kBrandon EbkenChief Information OfficerMs. Lauren MorrisAssociate Director of Investors RelationsMr. Todd MeyersVice President of Business Development & MarketingJohn T. Wynne MBASenior Vice President of Commercial Operations & Clinical Pharmacology UnitMr. Reinilde Heyrman M.D. (Age 63)Chief Medical Officer of Medical Department More ExecutivesKey CompetitorsIncyteNASDAQ:INCYCharles River Laboratories InternationalNYSE:CRLPRA Health SciencesNASDAQ:PRAHExelixisNASDAQ:EXELLaboratory Co. of AmericaNYSE:LHView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Sold 300 shares on 4/19/2024Ownership: 0.006%Handelsinvest InvesteringsforvaltningSold 399 shares on 4/19/2024Ownership: 0.002%Allspring Global Investments Holdings LLCBought 1,446 shares on 4/18/2024Ownership: 0.033%State of Michigan Retirement SystemBought 100 shares on 4/18/2024Ownership: 0.018%Diversified Trust CoSold 606 shares on 4/18/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions MEDP Stock Analysis - Frequently Asked Questions Should I buy or sell Medpace stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MEDP shares. View MEDP analyst ratings or view top-rated stocks. What is Medpace's stock price target for 2024? 4 analysts have issued twelve-month price targets for Medpace's shares. Their MEDP share price targets range from $273.00 to $452.00. On average, they expect the company's stock price to reach $382.00 in the next year. This suggests a possible upside of 2.1% from the stock's current price. View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts. How have MEDP shares performed in 2024? Medpace's stock was trading at $306.53 at the start of the year. Since then, MEDP stock has increased by 22.1% and is now trading at $374.32. View the best growth stocks for 2024 here. When is Medpace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024. View our MEDP earnings forecast. How can I listen to Medpace's earnings call? Medpace will be holding an earnings conference call on Tuesday, April 23rd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) announced its earnings results on Monday, February, 12th. The company reported $2.46 EPS for the quarter, topping analysts' consensus estimates of $2.22 by $0.24. The firm earned $498.40 million during the quarter, compared to analysts' expectations of $498.72 million. Medpace had a trailing twelve-month return on equity of 63.98% and a net margin of 15.00%. The business's quarterly revenue was up 26.5% on a year-over-year basis. During the same period last year, the company posted $2.12 EPS. What ETFs hold Medpace's stock? ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Argent Mid Cap ETF (AMID), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Invesco S&P MidCap Quality ETF (XMHQ), First Trust Health Care AlphaDEX Fund (FXH), Alpha Architect U.S. Quantitative Momentum ETF (QMOM) and Invesco S&P MidCap 400 Pure Growth ETF (RFG). What guidance has Medpace issued on next quarter's earnings? Medpace updated its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided earnings per share (EPS) guidance of 10.180-10.870 for the period, compared to the consensus earnings per share estimate of 9.960. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion. What is August Troendle's approval rating as Medpace's CEO? 268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG). When did Medpace IPO? Medpace (MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Medpace's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (3.15%), Los Angeles Capital Management LLC (0.85%), Congress Asset Management Co. MA (0.50%), Westwind Capital (0.14%), Annex Advisory Services LLC (0.13%) and Congress Wealth Management LLC DE (0.09%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MEDP) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceHow Biden has already won 2024Porter & CompanyUrgent alert: open this for a huge profit potentialTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.